Candel Therapeutics, Inc. CADL Net investment gains (losses)
Net investment gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingGainsLosses.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s net investment gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s net investment gains (losses)?
- Candel Therapeutics, Inc. (CADL) reported net investment gains (losses) of $22K in Q1 2026.
- How has Candel Therapeutics, Inc.'s net investment gains (losses) changed year-over-year?
- Candel Therapeutics, Inc.'s net investment gains (losses) decreased by 1.1% year-over-year, from $22.25K to $22K.
- What is the long-term trend for Candel Therapeutics, Inc.'s net investment gains (losses)?
- Over 2 years (2021 to 2025), Candel Therapeutics, Inc.'s net investment gains (losses) has grown at a -71.2% compound annual growth rate (CAGR), from $1.08M to $89K.
- What does net investment gains (losses) mean?
- Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.